Merck & Co. Jun 2, 2026 Merck & Co., Inc. (MRK) Presents at American Society of Clinical Oncology (ASCO) Annual Meeting 2026 - Slideshow - Seeking Alpha
Merck & Co. Jun 2, 2026 Merck shrinks headcount by 88 in New Jersey as $3B cost-cutting scheme advances - Fierce Pharma
Merck & Co. Jun 1, 2026 Merck & Co Inc Stock (MRK) Moved Down by 3.19% on Jun 1: A Full Analysis - TradingKey
Merck & Co. May 25, 2026 Veeva Systems' AI & Vault CRM Strength Signal More Upside Ahead - TradingView
Merck & Co. May 22, 2026 ASCO26: 5 data snapshots ahead of the year’s biggest cancer drug meeting - BioPharma Dive
Merck & Co. May 22, 2026 Fierce Pharma Asia—Merck-Kelun ADC’s triple wins; Tools in China licensing deals; Takeda’s $885M antitrust loss - Fierce Pharma
Merck & Co. May 22, 2026 ASCO26: Merck & Co., Moderna detail melanoma survival findings for cancer vaccine - FirstWord Pharma
Merck & Co. May 21, 2026 ASCO26: Merck & Co.'s ADC combo bests Keytruda alone in NSCLC - FirstWord Pharma
Merck & Co. May 21, 2026 ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer - Fierce Pharma
Merck & Co. May 20, 2026 EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study - TradingView
Merck & Co. May 19, 2026 Merck inks Keytruda supply pact to support Exelixis cancer trial - Fierce Biotech
Merck & Co. May 18, 2026 Results Reinforce Merck/Kelun’s Sac-TMT As Major TROP2 Player - Citeline News & Insights
Merck & Co. May 18, 2026 Merck ADC, licensed from China, hits mark in first big global trial - BioPharma Dive
Merck & Co. May 18, 2026 Merck & Co.'s first pivotal study of sac-TMT comes up trumps - FirstWord Pharma
Merck & Co. May 18, 2026 Microbiotica Announces Positive Results from its Phase 1b Trial (MELODY-1) of MB097, a Precision Microbiome Co-Therapy in Advanced Melanoma - The Manila Times